Drug repurposing screens and synergistic drug‐combinations for infectious diseases
British Journal of Pharmacology2017Vol. 175(2), pp. 181–191
Citations Over TimeTop 1% of 2017 papers
Abstract
This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.
Related Papers
- → COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery(2023)22 cited
- → Worldwide Publication Trends of Drug Repurposing and Drug Repositioning in the Science of Medicine (2003-2022)(2023)5 cited
- → Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2(2020)30 cited
- Machine Learning and Computational Approach to Repurposing FDA Approved Drugs(2020)
- → P62 SIMPATHIC: accelerating drug repurposing for rare neurological, neurometabolic and neuromuscular disorders by exploiting SIMilarities in clinical and molecular PATHology(2023)